Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

iology and Hypertension Program and Professor of Medicine at the University of Alabama at Birmingham in Alabama. "In addition to important blood pressure lowering, the combination of Tekturna and Diovan maintained a tolerability profile similar to that seen with either agent alone," said Dr. Oparil.

Tekturna received U.S. regulatory approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. This once-daily oral therapy is expected to be available by the end of March in U.S. pharmacies as 150 mg and 300 mg tablets.

A second study presented at the meeting compared Tekturna (150 mg or 300 mg alone or 300 mg in combination with HCTZ) to ramipril (5 mg or 10 mg alone or 10 mg in combination with HCTZ), another high blood pressure medicine in a class known as angiotensin converting enzyme (ACE) inhibitors (ACC presentation #1014). Results showed 61.4% of patients treated with the Tekturna-based therapy reached their blood pressure goal vs. 53.1% of patients treated with the ramipril-based therapy.

Tekturna and Diovan should be discontinued as soon as pregnancy is detected as they may harm an unborn baby, causing injury and even death. Women who plan to become pregnant should talk to their doctor about other treatment options before taking Tekturna or Diovan.

The need for new high blood pressure medicines is urgent given that this condition affects one in three adults in the U.S. and nearly 70% of these patients remain uncontrolled. In fact, many require two or more medications to reach their target blood pressure goal. Uncontrolled high blood pressure can increase the risk of cardiovascular disease, the world's leading cause of death.

"We are very encouraged by these results since they show Tekturna and Diovan are effective w
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... SGP ), a leader in hepatitis research, ... III studies of boceprevir, its,investigational oral hepatitis C ... virus (HCV) genotype 1. One study,will be in ... patients,who failed prior treatment (relapsers and nonresponders), an ...
... Laboratories, L.C., a,privately-owned biopharmaceutical company, today announced the ... to evaluate the safety and,efficacy of nitazoxanide in ... with chronic hepatitis C genotype 1 who have ... therapy (peginterferon and,ribavirin). The company expects to announce ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... 22, 2014) The International Communication Association will ... Seattle, Washington. The theme of the 2014 conference ... a networked and digital society. , Featuring over ... over 2,200 Communication scholars representing over 40 countries, ... communication conference in the world. This year,s conference ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... tools, but ,talking, computer program helped , , FRIDAY, ... the written questions American doctors have them answer ... question the usefulness of these screening tools, new ... year at the 2008 Clinical Congress of the ...
... WASHINGTON, Oct. 17 After a destructive,hurricane season that ... the American Public Health Association (APHA) wants to ensure,that ... storms and any other,potential emergencies you may face. With ... a new campaign aimed at encouraging Americans to,make sure ...
... AUBURN HILLS, Mich., Oct. 17 Chrysler LLC ... companies will bring an,innovative diabetes program to its ... developed with the Henry Ford Health System,and is ... and,care with existing workplace wellness initiatives. All employees ...
... into tobacco dependence published online today (Friday 17 October 2008) ... that recent ex-smokers who find exposure to other people,s cigarette ... those who find it unpleasant. , Led by Dr Hayden ... Unit at Barts and The London School of Medicine and ...
... ShotsTM Brings Public Health Message to Austin,s American,Heart ... Heart disease was the leading,cause of death ... in every,10 deaths. People with heart disease are ... complications from the flu. Therefore, the,U.S. Centers for ...
... break fundraising records for breast ... cancer research, SEATTLE, ... Breast Cancer Awareness month to raise money for breast,cancer research. This is ... to help breast cancer research and who has,not completed their will to ...
Cached Medicine News:Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:How Can Doing Your Will Online Help Cure Breast Cancer? 2
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... heart, the only therapy solution open to them is ... are not always readily available. For this reason, too ... list for a donor organ. , ,This is where ... a patient. On the one hand, these systems can ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay ... Advantage® Specialty System. The Nichols Advantage® 25-Hydroxyvitamin ... determination of 25-,hydroxyvitamin D (25-OH-D) and other ... or plasma to be used as an ...
Medicine Products: